Search
Ellagic acid
go.drugbank.com/drugs/DB08846InvestigationalEllagic acid is present in several fruits such as cranberries, strawberries, raspberries, and pomegranates. In pomegranates, there are several therapeutic compounds but ellagic acid is the most active and abundant. Ellagic acid is also p...
Categories: Cytochrome P-450 CYP2E1 Inhibitors, Cytochrome P-450 Enzyme InhibitorsUlipristal
go.drugbank.com/drugs/DB08867ApprovedInvestigationalA recent systematic review proclaimed that the majority of available evidence demonstrates an inhibitory effect on ovulation rather than a post-fertilization effect on the endometrium, which has been heavily
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesFingolimod
go.drugbank.com/drugs/DB08868ApprovedInvestigationalMultiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relap...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inducersCabozantinib
go.drugbank.com/drugs/DB08875ApprovedInvestigationalCabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 InhibitorsVemurafenib
go.drugbank.com/drugs/DB08881ApprovedInvestigationalVemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxiko...
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP1A2 InhibitorsMirabegron
go.drugbank.com/drugs/DB08893ApprovedInvestigationalMirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, ...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesTofacitinib
go.drugbank.com/drugs/DB08895ApprovedInvestigationalTofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid a...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesPonatinib
go.drugbank.com/drugs/DB08901ApprovedInvestigationalPonatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesCanagliflozin
go.drugbank.com/drugs/DB08907ApprovedInvestigationalCanagliflozin, also known as Invokana, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approv...
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsEperisone
go.drugbank.com/drugs/DB08992InvestigationalEperisone is an antispasmodic drug which relaxes both skeletal muscles and vascular smooth muscles, and demonstrates a variety of effects such as reduction of myotonia, improvement of circulation, and suppression of the pain reflex. It i...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates